Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

2(50.0%)

N/A

1(25.0%)

Phase 3

1(25.0%)

4Total

Phase 2(2)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06452082Completed

Risk in Devel Long-COVID in Contracting SARS-CoV-2 Infection After COVID-19 Vaccination in Relation to Vitamin D3 Suppl

Role: collaborator

NCT07448974Phase 3Not Yet Recruiting

Vitamin D and Type 2 Diabetes - Treat-To-Target

Role: collaborator

NCT04702087Not ApplicableUnknown

Omega 3, Leucine, Probiotic Lactobacillus Paracasei PS23 on Muscle Mass in Sarcopenic Subjects

Role: collaborator

NCT00415909Phase 2Terminated

TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients

Role: collaborator

NCT01477801Phase 2Unknown

Effects of Cholecalciferol Supplementation in Patients With Chronic Heart Failure and LOw vITamind D Levels

Role: collaborator

All 5 trials loaded